Program - Society of Toxicology

More documents

Recommendations

Info

44 th Annual Meeting and ToxExpo Program Description #1981 9:30 MODELING GENE NETWORKS IN THE NEURONAL ADAPTATION TO ALCOHOL. J. S. Schwaber. Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA. Sponsor: W. Slikker. #1982 10:00 SYSTEMS BIOLOGY AND DOSE RESPONSE ASSESSMENT. M. Andersen. Division of Biomathematics and Physical Sciences, CIIT, Research Triangle Park, NC. #1983 10:30 AN ±OMICS± APPROACH TO ELUCIDATE MECHANIMS OF DISRUPTED NEPHROGENESIS AND FUNCTIONAL INTERACTIONS BETWEEN AHR AND WILMS±TUMOR SUPPRESSOR GENE. K. S. Ramos. Department of Biochemistry and Molecular Biology, University of Louisville, Louisville, KY. #1984 11:00 COMPUTATIONAL SYSTEMS ANALYSIS OF DEVELOPMENTAL TOXICITY. T. B. Knudsen and A. V. Singh. Department of Molecular, Cellular and Craniofacial Biology, University of Louisville, Louisville, KY. Thursday Morning, March 10 8:30 AM to 11:30 AM Room RO8 WORKSHOP SESSION: CELLULAR/MOLECULAR MECHANISMS INVOLVED IN ENVIRONMENTAL CHEMICALS- INDUCED DOPAMINERGIC NEUROTOXICITY AND THE CONSEQUENCES ON NEURODEGENERATIVE DISEASES Chairperson(s): Anumantha Kanthasamy, Iowa State University, Ames, IA and Syed F. Ali, NCTR FDA, Little Rock, AR. Endorsed by: Neurotoxicology SS* Student Advisory Committee #1985 8:30 CELLULAR/MOLECULAR MECHANISMS INVOLVED IN ENVIRONMENTAL CHEMICALS- INDUCED DOPAMINERGIC NEUROTOXICITY AND THE CONSEQUENCES ON NEURODEGENERATIVE DISEASES. A. G. Kanthasamy. Iowa State University, Ames, IA. #1986 8:35 OXIDATIVE STRESS-SENSITIVE KINASE IN NEUROTOXINS-INDUCED SELECTIVE DOPAMINERGIC CELL DEATH: RELEVANCE TO PARKINSON’S DISEASE. A. G. Kanthasamy. Biomedical Sciences, Iowa State University, Ames, IA. #1987 9:15 ROLE OF PROINFLAMATORY CYTOKINES IN CHEMICALLY-INDUCED DOPAMINERGIC NEURODEGERATION. J. O’Callaghan. Neurotoxicology Laboratory, CDC/NIOSH, Morgantown, WV. #1988 9:55 BIOLOGICAL BASES FOR PCB INDUCED ALTERATION IN DOPAMINE-MEDIATED NEUROLOGICAL FUNCTION. R. F. Seegal 2 , K. L. Marek 3 , S. A. Factor 4 , R. J. McCaffrey 5 , R. F. Hasse 5 and A. G. Kanthasamy 1 . 1 Biomedical Sciences, Iowa State University, Ames, IA, 2 New York State Department of Health, Wadsworth Center, Albany, NY, 3 Institute of Neurodegenerative Disorders, New Haven, CT, 4 Albany Medical Center, Albany, NY and 5 University of Albany, Albany, NY. #1989 10:35 ROLE OF NITRIC OXIDE IN METHAMPHETAMINE-INDUCED DOPAMINERGIC NEUROTOXICITY IN MICE. S. F. Ali 1 and Y. Itzhak 2 . 1 Division of Neurotoxicology, NCTR/FDA, Jefferson, AR and 2 Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami, FL. THURSDAY Environmental neurotoxic chemical exposures are increasingly recognized as dominant risk factors in the etiology of many neurodegenerative disorders including Parkinson’s disease, Alzheimer’s disease Amyotrophic Lateral Sclerosis and Huntington’s disease. Exposure to environmental neurotoxic agents (metals, pesticides, PCBs and others) is often superimposed with the pathological hallmarks of neurodegenerative disorders. In recent years, cell death mechanisms have been investigated extensively. Despite this growing amount of information regarding the cell death process, little effort has been made to integrate this body of knowledge with the area of neurotoxicology and establish its relevance to neurodegenerative diseases. This workshop is designed to fill this gap by entertaining discussion of key cell death signaling molecules and other cellular targets during neurotoxic chemical exposures that may impact the disease process of neurodegenerative disorders. Specifically, novel findings obtained from both in vitro and in vivo models of neurotoxicity using state-ofthe-art approaches including toxicogenomics, transgenics, knock-outs, and RNA interference (RNAi) will be presented at this workshop. The workshop presentations are expected to uncover unifying concepts and set the groundwork for translation of key analogies between neurotoxicology research and neurodegenerative disorders. Also, questions provided by the speakers will serve as catalysts for discussion with the audience. Overall, this workshop is likely to accelerate understanding of the role of environmental neurotoxic agents in the etiopathogenesis of neurodegenerative disorders as well as to foster the development of novel therapeutic strategies. 202 SOT’s 44 th Annual Meeting
44 th Annual Meeting and ToxExpo Program Description Thursday Morning, March 10 8:30 AM to 11:30 AM Room RO6 WORKSHOP SESSION: SAFETY ASSESSMENT OF BIOLOGICAL THERAPEUTIC PRODUCTS- DEFINING THE SCIENTIFIC AND REGULATORY ISSUES Chairperson(s): Andrea Weir, U.S. FDA, Rockville, MD and Barbara Mounho, Amgen, Inc., Thousand Oaks, CA. Endorsed by: Immunotoxicology SS Regulatory and Safety Evaluation SS* Risk Assessment SS Toxicologic and Exploratory Pathology SS Women in Toxicology SS Biological therapeutic products (BTPs) are proteins derived from living organisms or produced via biotechnology means that have provided the medical community with novel, highly targeted therapies for the diagnosis and treatment diseases in humans. An integral part of the safety evaluation of these products is toxicology studies. BTP—induced toxicities are typically limited to their pharmacological mechanism of action; therefore, toxicology studies need to be conducted in an animal model that expresses the receptor or epitope that is recognized by the product. Frequently, a non-human primate (NHP) is the relevant model. In recent years, the quality of NHPs and the availability of methods for assessing toxicity in these animals have increased. In spite of these advances, many challenges remain in the safety assessment of BTPs. For example, only a very limited toxicological assessment can be conducted if the only relevant model is a chimpanzee. In such cases, toxicologists use innovative approaches, including the development of surrogate molecules, to conduct toxicology studies. Therefore, identification of novel methods is an ongoing effort in the BTP arena. Regardless of the animal model used, the potential for animals to mount an immune response to BTPs (immunogenicity) exists. Because immunogenicity can confound interpretation of toxicology studies, it is another challenge facing toxicologists that can result in the need for innovative approaches to safety assessment. Additionally, because immunogenicity can occur in humans receiving BTPs, the development of animal models to predict this effect in humans is an area of ongoing research. The need for innovative, flexible approaches when assessing the safety of BTPs is reflected in U.S. FDA and international regulatory documents. The topics covered in this workshop will provide toxicologists with the most current information on the unique scientific properties of BTPs and with state—of—the—art approaches to safety assessment of BTPs. #1990 8:30 SAFETY ASSESSMENT OF BIOLOGICAL THERAPEUTIC PRODUCTS — DEFINING THE SCIENTIFIC AND REGULATORY ISSUES. A. Weir 1 and B. J. Mounho 2 . 1 FDA/CDER, Rockville, MD and 2 Amgen Inc., Thousand Oaks, CA. #1991 8:35 DIFFERENCES BETWEEN SMALL MOLECULES AND BIOLOGICAL THERAPEUTIC DRUG PRODUCTS. B. Mounho. Toxicology, Amgen, Inc., Thousand Oaks, CA. #1992 9:05 IMMUNOGENICITY- IMPACT ON TOXICOLOGY STUDIES AND BEYOND. D. Wierda and H. Smith. Immunotoxicology, Eli Lilly Research Laboratories, Greenfield, IN. #1993 9:35 THE NONHUMAN PRIMATE AS AN ANIMAL MODEL FOR THE SAFETY EVALUATION OF BIOLOGICAL THERAPEUTIC PRODUCTS. J. Kapeghian. Discovery and Development Services, Charles River Laboratories, Sierra Division, Sparks, NV. #1994 10:05 ALTERNATIVE METHODS FOR THE SAFETY EVALUATION OF BIOLOGICAL THERAPEUTIC PRODUCTS — SURROGATE ANTIBODIES AND BEYOND. J. Clarke. BiogenIdec, Cambridge, MA. #1995 10:35 SAFETY ASSESSMENT OF BIOLOGICAL PRODUCTS — A REGULATORY PERSPECTIVE. H. Ghantous. FDA/CDER/ODEVI/DTBIMP, Rockville, MD. Thursday Morning, March 10 8:30 AM to 11:30 AM La Louisiane Ballroom B POSTER SESSION: ALTERNATIVES TO MAMMALIAN MODELS Chairperson(s): Irvin Schultz, Battelle Pacific Northwest Laboratories, Sequim, WA and George DeGeorge, MB Research Laboratories, Spinnerstown, PA. Displayed: 8:30 AM–11:30 AM Attended: 8:30 AM–10:00 AM #1996 NOVEL REPORTER GENE ASSAY FOR DEVELOPMENTAL TOXICITY TESTING. S. Schwengberg 1 , A. Ehlich 1 , H. Marquardt 2 , J. Hescheler 3 and H. Bohlen 1 . 1 Axiogenesis AG, Cologne, Germany, 2 Toxicology, University Hospital, Hamburg, Germany and 3 Neurophysiology, University Hospital, Cologne, Germany. #1997 VALIDATION STATUS OF THE HENS EGG TEST-CHORIOALLANTOIC MEMBRANE (HET- CAM) TEST METHOD. N. Choksi 1,2 , D. Allen 1,2 , C. Inhof 1,2 , J. Truax 1,2 , R. Tice 1,2 and W. Stokes 1 . 1 NICEATM, NIEHS, Research Triangle Park, NC and 2 ILS, Inc., Research Triangle Park, NC. #1998 GENE EXPRESSION SIGNATURES FOR CADMIUM, MERCURY, AND ACRYLAMIDE EXPOSURE IN CAENORHABDITIS ELEGANS. D. Jackson 1 , M. Szilagyi 2 , E. Gehman 2 and E. Clegg 1 . 1 US Army Center for Environmental Health Research, Fort Detrick, MD and 2 Geo-Centers, Inc., Fort Detrick, MD. #1999 CYTOKINE SECRETION PROFILES OF MOUSE DENDRITIC CELLS : IMPACT OF CELL TRAUMA. G. Beckwith 1 , C. J. Betts 1 , C. A. Ryan 2 , F. Gerberick 2 , R. J. Dearman 1 and I. Kimber 1 . 1 Syngenta CTL, Macclesfield, United Kingdom and 2 Procter & Gamble, Cincinnati, OH. #2000 MATRIX METALLOPROTEINASES AS BIOMARKERS FOR DIOXIN EXPOSURE IN DEVELOPING JAPANESE MEDAKA (ORYZIAS LATIPES). V. L. Prince, V. LaPrete, C. M. Villano and L. A. White. Biochemistry and Microbiology, Rutgers University, New Brunswick, NJ. #2001 EPIOCULAR HUMAN CELL CONSTRUCT: TISSUE VIABILITY AND HISTOLOGICAL CHANGES FOLLOWING EXPOSURE TO SURFACTANTS. M. E. Blazka 1 , M. Diaco 2 , J. W. Harbell 2 , H. Raabe 2 , A. Sizemore 2 , N. Wilt 2 and D. M. Bagley 1 . 1 Colgate-Palmolive Co., Piscataway, NJ and 2 Institute for In Vitro Sciences, Inc., Gaithersburg, MD. THURSDAY up-to-date information at www.toxicology.org 203
Page 1 and 2:
44 th Annual Meeting & ToxExpo TM P
Page 3 and 4:
Contents Program Overview .........
Page 5 and 6:
Annual Meeting Events Calendar (Con
Page 7 and 8:
Annual Meeting Events Calendar (Con
Page 9 and 10:
44 th Annual Meeting and ToxExpo Ne
Page 11 and 12:
44 th Annual Meeting and ToxExpo Co
Page 13 and 14:
Sheraton Hotel Map 44 th Annual Mee
Page 15 and 16:
Itinerary Planner Computer Stations
Page 17 and 18:
2005 Exhibitors (Continued) 44 th A
Page 19 and 20:
44 th Annual Meeting and ToxExpo To
Page 21 and 22:
44 th Annual Meeting and ToxExpo Ex
Page 23 and 24:
General Information 44 th Annual Me
Page 25 and 26:
44 th Annual Meeting and ToxExpo Ge
Page 27 and 28:
44 th Annual Meeting and ToxExpo Ge
Page 29 and 30:
2005 Award Winners The Society of T
Page 31 and 32:
2005 Award Winners (Continued) Enha
Page 33 and 34:
2004 Student Award Winners Colgate-
Page 35 and 36:
44 th Annual Meeting and ToxExpo Sc
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
INTERNATIONAL HARMONIZATION OF TECH
Page 49 and 50:
Saturday Afternoon, March 5 2:00 PM
Page 51 and 52:
44 th Annual Meeting and ToxExpo Pr
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154: 44 th Annual Meeting and ToxExpo Pr
Page 193 and 194: 44 th Annual Meeting and ToxExpo #1
Page 203: 44 th Annual Meeting and ToxExpo Pr
Page 227 and 228: Author Index 44 th Annual Meeting a
Page 229 and 230: Author Index (Continued) 44 th Annu
Page 247 and 248: SOT Affiliates for 2005 44 th Annua
Page 249 and 250: 44 th Annual Meeting and ToxExpo 20
Page 251 and 252: Headquarters Staff 44 th Annual Mee
Page 253 and 254: 44 th Annual Meeting and ToxExpo Ap
Page 255 and 256:
44 th Annual Meeting and ToxExpo Of
Page 257 and 258:
44 th Annual Meeting and ToxExpo So
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
up-to-date information at www.toxic
Page 267 and 268:
44 th Annual Meeting and ToxExpo To
Page 269:
44 th Annual Meeting & ToxExpo TM M
show all

Program - Society of Toxicology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?